DE69918687D1 - 4-phenylpiperidine zur behandlung von prutitischen hauterkrankungen - Google Patents

4-phenylpiperidine zur behandlung von prutitischen hauterkrankungen

Info

Publication number
DE69918687D1
DE69918687D1 DE69918687T DE69918687T DE69918687D1 DE 69918687 D1 DE69918687 D1 DE 69918687D1 DE 69918687 T DE69918687 T DE 69918687T DE 69918687 T DE69918687 T DE 69918687T DE 69918687 D1 DE69918687 D1 DE 69918687D1
Authority
DE
Germany
Prior art keywords
prutitic
phenylpiperidine
treatment
skin diseases
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69918687T
Other languages
English (en)
Other versions
DE69918687T2 (de
Inventor
Richard Edward Armer
Christopher James Dutton
David Morris Gethin
Stephen Paul Gibson
Julian Duncan Smith
Ivan Tommasini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of DE69918687D1 publication Critical patent/DE69918687D1/de
Application granted granted Critical
Publication of DE69918687T2 publication Critical patent/DE69918687T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C07D211/28—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69918687T 1998-05-18 1999-05-17 4-Phenylpiperidine zur Behandlung von pruritischen Hauterkrankungen Expired - Fee Related DE69918687T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9810671 1998-05-18
GBGB9810671.9A GB9810671D0 (en) 1998-05-18 1998-05-18 Anti-pruritic agents
PCT/IB1999/000886 WO1999059971A1 (en) 1998-05-18 1999-05-17 Novel 4-phenylpiperidines for the treatment of pruritic dermatoses

Publications (2)

Publication Number Publication Date
DE69918687D1 true DE69918687D1 (de) 2004-08-19
DE69918687T2 DE69918687T2 (de) 2005-07-28

Family

ID=10832267

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69918687T Expired - Fee Related DE69918687T2 (de) 1998-05-18 1999-05-17 4-Phenylpiperidine zur Behandlung von pruritischen Hauterkrankungen

Country Status (18)

Country Link
US (1) US6610711B2 (de)
EP (1) EP1077940B1 (de)
JP (1) JP2002515486A (de)
AP (1) AP9901535A0 (de)
AT (1) ATE271038T1 (de)
AU (1) AU3531299A (de)
BR (1) BR9910609A (de)
CA (1) CA2332538C (de)
DE (1) DE69918687T2 (de)
DK (1) DK1077940T3 (de)
ES (1) ES2230846T3 (de)
GB (1) GB9810671D0 (de)
GT (1) GT199900067A (de)
MA (1) MA26630A1 (de)
PT (1) PT1077940E (de)
TN (1) TNSN99095A1 (de)
WO (1) WO1999059971A1 (de)
ZA (1) ZA993364B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9912417D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912413D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912415D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912410D0 (en) * 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912411D0 (en) * 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912416D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
MXPA03011886A (es) * 2001-07-05 2005-03-07 Lundbeck & Co As H Piperidinias anilinicas sustituidas como antagonistas selectivos de mch.
US6727264B1 (en) 2001-07-05 2004-04-27 Synaptic Pharmaceutical Corporation Substituted anilinic piperidines as MCH selective antagonists
JP4155522B2 (ja) * 2001-10-22 2008-09-24 ファイザー・プロダクツ・インク オピオイド受容体アンタゴニストとしての３−アザビシクロ（３．１．０）ヘキサン誘導体
BR0214295A (pt) * 2001-11-19 2004-11-09 Elan Pharm Inc Composto, método para tratar um paciente que tem ou prevenir um paciente de adquirir uma doença ou condição, e, método para produzir um composto
ES2201908B1 (es) * 2002-05-29 2005-02-16 Laboratorios Del Dr. Esteve, S.A. Pienso suplementado con ketoprofeno y su empleo en el tratamiento de procesos que cursan con fiebre, inflamacion y/o dolor, en un colectivo de animales, de forma simultanea.
BRPI0409307A (pt) * 2003-04-14 2006-04-25 Pfizer Prod Inc derivados de 3-azabiciclo[3.2.1]octano
FR2872416B1 (fr) * 2004-07-01 2006-09-22 Oreal Utilisation de derives de piperidine pour lutter contre les rides
EP2767163A1 (de) * 2005-02-17 2014-08-20 Abbott Laboratories Transmukosale Verabreichung von Arzneimittelzusammensetzungen zur Behandlung und Vorbeugung von Erkrankungen bei Tieren
CA2632030A1 (en) * 2005-12-15 2007-06-21 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
MY145633A (en) 2006-03-01 2012-03-15 Theravance Inc 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
WO2008014199A2 (en) * 2006-07-28 2008-01-31 Boehringer Ingelheim International Gmbh Sulfonyl compounds which modulate the cb2 receptor
KR20090069318A (ko) * 2006-09-25 2009-06-30 베링거 인겔하임 인터내셔날 게엠베하 Ｃｂ2 수용체를 조절하는 화합물
TWI409067B (zh) 2007-02-28 2013-09-21 Theravance Inc ８-氮雜雙環〔３．２．１〕辛烷化合物之結晶型
US7947710B2 (en) * 2007-08-27 2011-05-24 Theravance, Inc. Disubstituted alkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
TWI423801B (zh) 2007-08-27 2014-01-21 Theravance Inc 作為μ類鴉片受體拮抗劑之８－氮雜雙環〔３．２．１〕辛基－２－羥基苯甲醯胺化合物
ES2465621T3 (es) * 2007-08-27 2014-06-06 Theravance, Inc. Compuestos de heteroarilalquil-8-azabiciclo[3.2.1]octano, como antagonistas de los receptores opiodes mu
US7902221B2 (en) * 2007-08-27 2011-03-08 Theravance, Inc. Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
EP2217565B1 (de) * 2007-11-07 2013-05-22 Boehringer Ingelheim International GmbH Cb2 rezeptor-modulierende verbindungen
EP2326629B1 (de) * 2008-07-10 2013-10-02 Boehringer Ingelheim International GmbH Den cb2-rezeptor modulierende sulfonverbindungen
CA2737645A1 (en) * 2008-09-25 2010-04-01 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the cb2 receptor
US8299103B2 (en) 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
WO2010147791A1 (en) 2009-06-16 2010-12-23 Boehringer Ingelheim International Gmbh Azetidine 2 -carboxamide derivatives which modulate the cb2 receptor
EP2480544A1 (de) * 2009-09-22 2012-08-01 Boehringer Ingelheim International GmbH Verbindungen für selektive cb2-rezeptormodulation
EP2523936A1 (de) 2010-01-15 2012-11-21 Boehringer Ingelheim International GmbH Cb2 rezeptor-modulierende verbindungen
US8329735B2 (en) 2010-03-05 2012-12-11 Boehringer Ingelheim International Gmbh Tetrazole compounds which selectively modulate the CB2 receptor
WO2012012307A1 (en) 2010-07-22 2012-01-26 Boehringer Ingelheim International Gmbh Sulfonyl compounds which modulate the cb2 rece
EP2803668A1 (de) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Neuartige (Cyano-dimethyl-methyl)-isoxazole und -[1,3,4]-thiadiazole
CN106278914B (zh) * 2016-08-19 2018-04-13 四川福思达生物技术开发有限责任公司 一种增产胺的合成工艺
CN116440882B (zh) * 2023-01-16 2024-09-20 浙江纽龙合成材料制造有限公司 一种基于端烯基活化的疏水分离层析介质及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR206937A1 (es) * 1974-09-06 1976-08-31 Lilly Co Eli Procedimiento para preparar compuestos de 1-sustituido-4-alquil-4-fenil-piperidina
NZ224236A (en) 1987-04-16 1990-08-28 Lilly Co Eli Trans 3,4 pyridine derivatives and pharmaceutical compositions
US5159081A (en) * 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
CZ284993B6 (cs) 1991-03-29 1999-04-14 Eli Lilly And Company Derivát piperidinu
GB9507203D0 (en) * 1995-04-07 1995-05-31 Smithkline Beecham Plc Novel compounds
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
US6159979A (en) * 1997-04-18 2000-12-12 Smithkline Beecham P.L.C. Bicyclic aryl or a bicyclic heterocyclic ring containing compounds having a combined 5HT1A, 5HT1B and 5HT1D receptor antagonistic activity

Also Published As

Publication number Publication date
ES2230846T3 (es) 2005-05-01
EP1077940B1 (de) 2004-07-14
WO1999059971A1 (en) 1999-11-25
MA26630A1 (fr) 2004-12-20
AP9901535A0 (en) 1999-06-30
US6610711B2 (en) 2003-08-26
CA2332538C (en) 2005-08-02
GB9810671D0 (en) 1998-07-15
DK1077940T3 (da) 2004-11-01
JP2002515486A (ja) 2002-05-28
US20030078282A1 (en) 2003-04-24
ATE271038T1 (de) 2004-07-15
AU3531299A (en) 1999-12-06
BR9910609A (pt) 2001-01-09
GT199900067A (es) 2000-11-04
CA2332538A1 (en) 1999-11-25
ZA993364B (en) 2000-12-01
PT1077940E (pt) 2004-10-29
EP1077940A1 (de) 2001-02-28
DE69918687T2 (de) 2005-07-28
TNSN99095A1 (fr) 2005-11-10

Similar Documents

Publication Publication Date Title
ATE271038T1 (de) 4-phenylpiperidine zur behandlung von prutitischen hauterkrankungen
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
ATE417602T1 (de) Mittel zur behandlung von erkrankungen der speiseröhre
DE69829921D1 (de) Vorrichtung zur Behandlung von Körpergewebe
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
DE69924750D1 (de) Gerät zur thermischen behandlung von gewebe
DE69827424D1 (de) Vorrichtung zur gesteuerten thermischen Behandlung von Gewebe
DE69903543D1 (de) Formulierungen zur behandlung von magen-speiseröhren reflux
DE69739303D1 (de) Vorrichtung zur thermischen behandlung von gewebe
DE50009504D1 (de) Verwendung von retigabin zur behandlung von neuropathischen schmerzen
DE69936335D1 (de) Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen
DE69838338D1 (de) Verwendung von antimykotica zur topischen behandlung von pilz-induzierten schleimhautentzündungen
DE69926385D1 (de) Behandlung von geweben
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE69836752D1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
DE69509544D1 (de) Zusammensetzung zur behandlung ovarieller östrogenabhängiger krankheiten
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60028863D1 (de) Elektrochirurgisches Handstück zur Behandlung von Gewebe
DE69711311D1 (de) Vorrichtung zur thermischen Behandlung von Gewebe
DE69824576D1 (de) Verwendung von tetrahydropyridinderivaten zur herstellung von arzneimitteln zur behandlung demyelinisierender erkrankungen
DE69943089D1 (de) Methode zur behandlung von staphylokokkeninfektionen
DE69807466D1 (de) Triptolid-derivate nützlich zur behandlung von autoimmunkrankheiten
DE69737067D1 (de) Vakzine zur behandlung von mycosen
DE69829217D1 (de) Vorrichtung zur therapeutischen behandlung von blutgefässen
DE69936994D1 (de) Verfahren zur behandlung von okularen neovaskularen erkrankungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee